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A wide range of lymphokines have been described that enhance the prolifer- 
ation of B lymphocytes, including interleukin 1 (I L-l)l (1), IL-2 (2, 3), interferon 
(IFN) (4), and several B cell growth factors (BCGF) or B cell stimulatory factors 
(BSF) (5-10).  However, the precise molecular distinctions among these factors 
and  the exact role  that  each  plays in  B  cell  function  remains unclear.  Many 
important questions regarding the biology and chemistry of these lymphokines 
are unanswered, in part because sufficient quantities of purified proteins have 
not been available. 
Recently, substantial progress has been made in the purification and chemical 
and biologic characterizations of several lymphokines.  IL-1  has been purified 
(11) and cloned (12), as have IL-2 (13-15) and various IFN (16-18).  However, 
investigations related to BCGF have lagged behind those of other lymphokines 
because of several major problems.  First,  it has been difficult or impossible to 
completely separate IL-2 from BCGF when both are present in the same culture 
supernatant (19). Second, the currently available assay systems for BCGF, which 
depend on costimulation of normal B cells with antigen (20) or surface membrane 
immunoglobulin crosslinking agents such as Staphylococcus aureus Cowan I (SAC) 
(21),  are time consuming and  insensitive.  Third,  monoclonal antibodies  have 
been invaluable in the purification of certain lymphokines. In the purification of 
IL. 2, Smith et al. (I 3) found that a monoclonal antibody was necessary to detect 
IL-2 in column fractions because functional activity, as defined by the ability to 
enhance the proliferation of an IL-2-dependent cell line, was lost during purifi- 
cation. No monoclonal antibody has yet been developed to any human BCGF, 
3  Abbreviations used in this paper:  BCGF, B cell growth factor;  BSF,  B cell  stimulation factor; 
HMW, high molecular weight; HPLC, high performance liquid chromatography; IFN, interferon; 
1L-I  and IL-2, interleukin 1 and 2; LMW, low molecular weight; PBS, phosphate-buffered saline; 
PHA, phytohemagglutinin;  SAC, Staphylococcus aureus Cowan I; SDS-PAGE, sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis. 
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although  a  monoclonal antibody has recently been developed to a  murine,  low 
molecular weight (LMW) BCGF termed BSF-I (22). 
We  have  recently described  production  of a  high  molecular weight  (HMW) 
BCGF by the  human  B  lymphoma line,  Namalva, and a  human T  cell  line,  T- 
ALL (9).  The HMW-BCGF-containing supernatants produced  by these lines in 
serum-free  media  lack  IL-1,  1L-2,  and  IFN  activity.  Thus,  these  supernatants 
represent an ideal starting material for the purification of HMW-BCGF.  In this 
paper,  we  describe  purification  of this  HMW-BCGF  to apparent  homogeneity 
and the production of a  monoclonal antibody to the purified protein. 
Materials and  Methods 
Cell Lines and HMW-BCGF Production.  Namalva has been grown in our laboratory for 
several years, and T-ALL was kindly provided by Dr. Jun Minowada (Loyola University, 
Chicago,  IL). Both  lines were grown  in  HB102  media (Hana Biologics, Inc., Berkeley, 
CA) without serum at a cell density of 106 cells/ml. Cells were stimulated with phytohe- 
magglutinin (PHA) (Burroughs Wellcome Research Laboratories, Beckenham, England) 
at a concentration of 1 #g/ml for 72 h, and then cell-free supernatant was harvested, as 
described (9). 
BCGF Assay.  Human B cells were purified as previously described (9) from tonsils or 
peripheral blood. Supernatants or column fractions to be assayed for BCGF activity were 
added to B cells (5  X  104/ml) in 96-well, flat-bottomed microtiter plates (Costar 3596; 
Data Packaging Corp., Cambridge, MA) in the presence of 15/,g/ml of F(ab')2 goat anti- 
human  IgM heavy chain-specific  anti-/, (Cappel  Laboratories, Cochranville,  PA).  Over 
the last 16 h of the 72-h culture period,  1 ~Ci of [3H]thymidine (New England Nuclear, 
Boston,  MA)  was added  to  each  well.  Cells were  then  harvested  using a  Skatron  cell 
harvester  (Skatron,  Inc.,  Sterling,  VA),  and  the  incorporation  of [3H]thymidine  was 
measured by standard liquid scintillation counting techniques. 
T  Cell Proliferation Assay.  T  cells were purified from peripheral blood by rosetting 
once with aminoethylisothiouronium bromide-treated sheep erythrocytes as previously 
described (24).  Supernatants or column fractions to be assayed for T  cell proliferation- 
inducing activity were added to 96-well, flat-bottomed microtiter plates containing 10 ~ T 
cells in RPMI 1640 with 10% fetal calf serum. Culture was maintained for 96 h, and cells 
were pulsed with [3H]thymidine for the last  18  h  of culture.  Cells were then harvested 
and [~H]thymidine incorporation was measured. 
IL-2 Assay.  IL-2 activity  was  assessed  as  previously described  (25)  using  the  IL-2- 
dependent T  cell line HT-2 kindly provided by Dr. David Volkman (National Institutes 
of Health). 
Production of Anti-HBl02 Affinity Matrix.  Although serum-free HB102 medium con- 
tains some proteins, the type and amount are not public information. Antibodies to these 
proteins were produced in rabbits by immunization with concentrated HB102 proteins in 
complete Freund's adjuvant (Sigma Chemical Co., St.  Louis, MO). Serum was collected 
after three immunizations, and IgG was purified by octanoic acid precipitation (23).  The 
lgG was coupled to cyanogen bromide-activated Sepharose (Pharmacia Fine Chemicals, 
Piscataway, N  J) by a minor modification of the method of Tan-Wilson et al. (31). 
HMW-BCGF Purification Scheme.  The method for purification of HMW-BCGF is shown 
schematically in Fig.  1. 10 liters of PHA-stimulated T-ALL supernatant was concentrated 
to a volume of 10 ml using a  Minitan concentrator with  10,000-mol-wt exclusion mem- 
branes (Millipore Corporation, Bedford, MA). 
Concentrated T-ALL supernatant (1 ml) was introduced onto a  15 ml column contain- 
ing rabbit anti-media IgG and  incubated  with  the  resin  for  120  rain  at 4°C.  Material 
containing BCGF was washed through the column with phosphate-buffered saline (PBS). 
Bound material was eluted with 0.2 M glycine (pH 3.0) and the column was washed with 
PBS before the next sample was applied. 
The BCGF-containing pool from the anti-media column was concentrated to 5 ml by AMBRUS  ET  AL.  1321 
FIGURE 1. 
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Protocol for purification  of HMW-BCGF from T-ALL supernatant. 
positive pressure  using a  YM10  membrane  (Amicon Corp.,  Scientific System  Division, 
Danvers,  MA).  Samples of 500  ul  were  then  entered  repetitively  onto a  1.5  X  15  cm 
ultrasphere-ods reverse phase, high performance liquid chromatography column (HPLC) 
(Beckman Instruments,  Irvine, CA) and eluted with a gradient of 10-100% acetonitrile 
in water at a buffer flow rate of 0.5 ml/min.  Fractions were collected every 2 min. Each 
fraction was dialyzed individually against RPMI 1640 and then assayed for BCGF activity. 
Active fractions were pooled and again concentrated to 5 ml using a YM 10 membrane. 
This material  was applied  in  1-ml aliquots  to a  TSK-G3000 SW HPLC sieving column 
(Toyo Soda Co., Ltd., Tokyo, Japan) and eluted with PBS at a flow rate of 1 ml/min. 60 
fractions were collected and assayed for BCGF activity. Active fractions were pooled and 
applied to a preparative isoelectric focusing bed containing Pevicon (Accurate Chemical 
and  Scientific Corp.,  Westbury,  NY).  Isoelectric focusing was performed as previously 
described  (9).  The  bed  was  then  separated  into  24 slices,  and  the  pH  of each  section 
measured.  After  removal  of the  Pevicon  by  centrifugation,  individual  fractions  were 
dialyzed in  RPMI  1640 and again assayed for BCGF activity. Active fractions between 
pH  6.7  and  7.8 were pooled. The active fraction at pH 4.9 was discarded because this 
was believed to be primarily albumin with some nonspecifically bound HMW-BCGF. This 
pool was concentrated to 0.5 ml, and the entire sample entered onto a TSK-3000 HPLC 
sieving column (Toyo Soda Co., Ltd.). The column was again eluted with PBS. One major 
peak of activity was obtained. Some of the material from this fraction was iodinated using 
the  Bolton-Hunter  reagent  (26).  The  iodinated  material  was  evaluated  for  purity  by 
autoradiography after electrophoresis in a  10%  sodium dodecyl sulfate (SDS)-polyacryi- 
amide gel (27). 
Evaluation of Specific Binding of HMW-BCGF.  ]~SI-HMW-BCGF produced as described 
above  was  added  at  -50,000  cpm  to  tubes  containing  105  unactivated  B  cells,  SAC- 
activated B cells (48 h after SAC activation), unactivated T  cells, or PHA-activated T  cells 
(48 h after PHA stimulation) in a total volume of 500 ~tl RPMI  1640. Unlabeled  HMW- 
BCGF or IL-2 were added  to different tubes at different concentrations and each tube 
briefly shaken.  Tubes were allowed to sit at  4°C for 8  h after which they were washed 
three times with PBS. After washing, cell-associated radioactivity was quantitated. 
Production  of Monoclonal Antibody to HMW-BCGF.  BALB/c mice were immunized with 
purified HMW-BCGF in complete Freund's adjuvant at 2-wk intervals for a total of three 1322  MONOCLONAL  ANTIBODY  TO  HMN-BCGF 
immunizations.  4  d  after the third  immunization,  the  spleens were harvested and  the 
mononuclear cells dispersed by passage over a fine wire mesh.  Mononuclear cells were 
fused to the mouse myeloma NS-1 at a ratio of 2:1  using a standard polyethylene glycol 
fusion technique (28).  Hybridomas were selected in  hypoxanthine/aminopterin/thymi- 
dine-containing media as described (28) and then clones were established by growing cells 
in  96-well,  flat-bottomed plates seeded at 0.3  cells per well.  Supernatants from clones 
were assayed for their ability to block anti-# and HMW-BCGF-driven B cell proliferation. 
Positive wells were recloned, and then the clone that optimally blocked anti-# and HMW- 
BCGF-driven B cell proliferation was evaluated for its ability to bind to HMW-BCGF by 
Western blotting. Western blotting was performed as described previously (29). The clone 
BCGF/1/C2 was then grown in the ascites of pristane-treated BALB/c female mice as 
previously described (30).  Ascites was harvested, and.lgG was purified by precipitation 
with octanoic acid (23) as previously described. The quantity of IgG present was estimated 
by measuring the absorbance at 280 nm (E~8% 1 cm IgG =  14).  Some of this IgG anti- 
BCGF was coupled to Sepharose as described above. 
Internal Labeling of HMW-BCGF.  Internal labeling of HMW-BCGF was accomplished 
by growing T-ALL to 106/ml in HB102. Cells were then washed with PBS and placed in 
RPMI  1640 deficient in leucine, lysine, and glycine at a cell density of 106 cells/ml in a 
total volume of 4 liters. Then, 5 #Ci each of [3H]leucine (> 140 Ci/mmol), [~H]lysine (>5 
Ci/mmol), and [3H]glycine (30-60 Ci/mmol) (New England Nuclear) were added to the 
culture flask and the cells were stimulated with PHA at  1 #g/ml. Cell-free supernatant 
was harvested 72 h later, concentrated, and applied to monoclonal anti-BCGF-Sepharose 
columns. Internally labeled HMW-BCGF was detected in polyacrylamide gels by fluorog- 
raphy after treatment with Enhance (New England Nuclear). 
Results 
Pur~cation  of HMW-BCGF.  The  HMW-BCGF  produced  by  Namalva  has 
been described previously in detail (9). T-ALL stimulated with PHA produces a 
BCGF of similar  molecular weight whose activity on anti-#-stimulated,  unfrac- 
tionated peripheral blood B cells is demonstrated in Table I. The optimal BCGF 
activity was seen at a  25% vol/vol concentration of supernatant, a dose response 
similar  to  the  HMW-BCGF  produced  by  Namalva.  For purposes  of assessing 
functional recovery during purification, we have defined one unit as the amount 
of  HMW-BCGF  necessary  to  give  half-maximal  stimulation,  with  maximum 
defined as the proliferation in  25%  crude Namalva supernatant.  Half-maximal 
stimulation  of B  cell  proliferation  by  unfractionated  T-ALL  supernatant  oc- 
curred at ~15% vol/vol (equivalent to 30 tsl per 200-~1 well). Thus, since  1 U  is 
contained in  30 #1  of crude supernatant,  our starting  material  of 10  liters for 
purification contains  ~330,000  U  of BCGF activity. Incubation of B  cells with 
PHA  alone  in  the  functional  assay  caused  no  significant  proliferation,  which 
demonstrates  that  PHA  does  not  play  a  significant  role  in  the  proliferation- 
inducing activity of the crude supernatant. 
Because the T-ALL supernatant lacks IL-1, IL-2, and IFN activity, purification 
was concerned with removing media proteins (primarily albumin and transferrin), 
other T-ALL secretory products, and PHA. The PHA used shows some size and 
change  heterogeneity,  with  the  primary  species  having a  molecular weight  of 
100,000 and a pI of 5.3 (data not shown). 
After  1,000x concentration, the  HMW-BCGF was absorbed with an affinity 
matrix containing antibodies to the proteins in HB 102. This significantly reduced 
the quantity of contaminating protein. ~36.70D  units of protein were applied AMBRUS  ET  AL.  1323 
TABLE  I 
BCGF Activity of Supernatant from T-ALL and Namalva Lines after 
Stimulation wth PHA 
Factor added  [SH]Thymidine 
incorporation 
None 
PHA 
T-ALL (F) 
Namalva 
1,063 +  184 
1,676 -+ 4 
50% (vol/vol)  12,747 +  119 
25%  23,893 -+ 1,100 
10%  6,891  +  1,061 
5%  1,297 -+ 456 
25% (vol/vol)  21,082 +  913 
B  ceils purified as described in  Materials and  Methods were stimulated 
with 15 #g/ml anti-t~ and placed in 96-well Costar plates at a concentration 
of 5 x  104 cells per well in  10%  fetal calf serum with RPMI and factors 
added. Cells were kept in culture at 37°C in 5% CO2 for 72 h and pulsed 
with 1 #Ci/well of [SH]thymidine for the last  18 h. Cells were harvested 
at 72 h, and incorporation of [3H]thymidine was measured with a scintil- 
lation counter. 
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FIGURE 2.  BCGF-containing T-ALL supernatant entered on a  1.5 ×  15 cm ultrasphere-ods 
reverse phase HPLC column and eluted with a  10-100%  gradient of acetonitrile. Fractions 
were individually dialyzed and then assayed for BCGF activity. (  ) Absorbance, (--.) BCGF 
activity. The bar graphs at the left represent the assay controls: O +  a~t and/3 +  a~ +  HMW- 
BCGF. 
to the immunoabsorbant; the drop-through containing the HMW-BCGF activity 
had only 11.80D  units. The glycine eluate had 21.50D  units. 
The remainder  of the purification  scheme is demonstrated by representative 
column and isoelectric focusing runs in Figs. 2-5. The first step (Fig. 2) consisted 
of fractionating  the immunoabsorbant drop-through  on a  revers  e phase HPLC 
column.  The  BCGF activity  along  with  a  large  amount  of additional  protein 
eluted from the column at an acetonitrile concentration  between 22 and  25%. 
The next step involved gel permeation  on TSK-G3000 SW column. This sepa- 
rated the BCGF activity into two peaks, associated with two major absorbance 
peaks (Fig. 3). These peaks occur in the molecular weight ranges of 150-200,000 
and 60-80,000.  This may imply that an even higher (i.e., ~200,000 vs. 60,000) 
molecular  weight  BCGF exists,  but  we  have  not  yet explored  this  possibility. 1324  MONOCLONAL  ANTIBODY  TO  HMN-BCGF 
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FIGURE 3.  BCGF-containing fi-actions from reverse phase HPLC were pooled and entered 
on a TSK-G3000 SW HPLC sieving column. Fractions were eluted with PBS and assayed for 
BCGF activity. (  ) Absorbance, (---) BCGF activity. The bar graph at the left represents 
the controls of the BCGF assay. 
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FIGURE 4.  BCGF-containing fractions from TSK-G3000 SW column were pooled and sub- 
jected to isoelectric focusing in Pevicon as described in Materials and Methods. The focusing 
bed was then sliced into 24  sections, and the pH  of each slice measured.  After removal of 
Pevicon by centrifugation, individual fractions were dialyzed in RPMI  1640 and then assayed 
for BCGF activity. (  ) BCGF activity. The bar graphs at the left represent the controls for 
the BCGF assay. 
Active  fractions  from  the  G3000  SW  column  were pooled  and  subjected  to 
isoelectric focusing  in  a  bed  of Pevicon  (Fig.  4).  Three  activity  peaks  were 
obtained.  Two  peaks,  with  isoelectric points  of 6.7  and  7.8,  are  identical  to 
activity peaks described for Namalva-synthesized HMW-BCGF (9). The activity 
peak at pH 4.9 presumably represents a BCGF albumin complex, since albumin 
has an  isoelectric point  of 4.8-4.9.  Therefore, this  low pH  activity peak  was 
discarded.  The  peaks  with  isoelectric points  of 6.7  and  7.8  were pooled  for 
further purification. 
The final purification step involved a  second, smaller HPLC sieving column 
(Fig. 5), which resolved one major BCGF activity peak at 60,000 with very little 
absorbance  at  280  nm.  This  activity  peak  lacked  the  ability  to  enhance the 
proliferation of resting T  cells (data not shown),  but contained ~1,000  U  of 
BCGF activity.  This  represents an overall yield of the purification of ~0.3%. 
Table  II  outlines  the  approximate  yield  from  the  various  purification  steps. AMBRUS  ET  AL.  1325 
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FIC,  URE  5.  BCGF-containing  fractions  at  pH  6.7  and  7.8  from  isoelectric  focusing  were 
pooled and entered on a  TSK-3000  HPLC sieving column. Fractions were eluted with PBS 
and assayed for BCGF activity. (  ) Absorbance, (---) BCGF activity. The bar graphs at the 
left represent the controls for the BCGF assay. 
TABLE  II 
Purification  of HMW-BCGF 
Total  Step  Total protein*  Specific activity  Times purified  activity* 
U  mg  #/mg 
Crude supernatant  ~  330,000  145.0  2.5 x  103  -- 
Anti-HB102 affinity  250,000  44.0  5.6 X  l0 s  2.2 
matrix 
Reverse phase HPLC  46,000  0.55  83 x  103  32.2 
TSK-G3000SW  HPLC  40,000  0.30  133 X  103  56.0 
Pevicon isoelectric  1,200  ND |  --  -- 
focusing 
TSK-3000 HPLC  1,000  <0.002  ~500 X  lO  s  >200.0 
* Activity is expressed in half-maximal stimulation units as described in Results. 
* Protein was measured by absorbance at 280 nm either manually (steps 1 and 2) using a  Beckman 
DU50 spectrophotometer or by the spectrophotometer monitoring the chromatographic separa- 
tions; integration  units from the HPLC spectrophotometer were converted to protein weight by 
comparing integration  units  from  known  amounts  of bovine  serum  albumin  chromatographed 
under the same conditions. 
~Starting material was 10 liters of crude supernatant. 
It Not done. 
Because we were unable to quantitate protein in the final pure preparation, exact 
specific activity of the purified HMW-BCGF could not be determined. This final 
pool  was radiolabeled  using  the  Bolton-Hunter  reagent  because methods  that 
iodinated the tyrosine (5) in the molecule destroyed functional activity (data not 
shown). The radiolabeled, functionally active fraction from the TSK3000 column 
was  subjected  to  SDS-polyacrylamide  gel  electrophoresis  (PAGE)  and  autora- 
diography.  Fig.  6  demonstrates  that  radiolabeled protein  showed only a  single 
band at 60,000 mol wt. Thus, by this criterion, the HMW-BCGF was biochemi- 
cally as well as functionally pure. 1326  MONOCLONAL ANTIBODY TO  HMN-BCGF 
FIGURE 6.  A small  amount of purified HMW-BCGF  was iodinated using the Bolton-Hunter 
reagent. The iodinated material was electrophoresed in a 10% SDS-polyacrylamide  gel and 
then evaluated by autoradiography. (1) Protein standards; (2) iodinated HMW-BCGF. 
Selective Binding of Pur~ed HMW-BCGF to Activated B Cells.  We investigated 
whether the purified protein bound to B cells, which is a requirement for a true 
BCGF (20,  32, 33).  Iodinated HMW-BCGF was incubated with both resting and 
activated B and T  cells, and cell-associated radioactivity was assessed. Nonspecific 
binding of iodinated  HMW-BCGF was assessed by simultaneous incubation of 
cells with radiolabeled HMW-BCGF and a  20-fold excess of unlabeled purified 
protein  (Fig.  7A).  B cells were activated with SAC, and T  cells were activated 
with  PHA  for 48  h  before the binding assay.  Neither resting B or T  cells nor 
activated  T  cells  showed  any specific  binding  of the  125I-HMW-BCGF,  while 
activated  B  cells  bound  the  labeled  factor.  Binding  of  125I-HMW-BCGF  to 
activated B cells was inhibited in a dose-dependent manner by increasing amounts 
of unlabeled HMW-BCGF (Fig.  7A).  Moreover,  1L-2 purified from the Jurkat 
line  (kindly  provided  by  the  Food  and  Drug  Administration,  Bethesda,  MD) 
failed to inhibit the binding of 12"~I-HMW-BCGF  to activated B cells (Fig.  7B). 
This  supports  the  notion  that  the  association  between  12"~I-HMW-BCGF  and 
activated  B  cells involved specific binding of factor to a  cell  surface receptor. 
Furthermore,  these  data  demonstrate  that  the  radiolabeled  protein  we  had 
purified indeed  bound  to activated  B  cells quite  specifically, as required  of a 
BCGF. 
Monoclonal  Antibody  to HMW-BCGF.  The data suggested that the 60,000 mol 
wt protein  we  had purified  contained the  HMW-BCGF  biologic  activity.  Our 
next goal was to develop a  monoclonal antibody to the factor in order to allow 
rapid purification of additional  HMW-BCGF,  rapid  screening of supernatants 
for the presence of HMW-BCGF, and studies of the chemistry and biochemistry 
of this  and  other  B  cell  regulatory  lymphokines.  Female  BALB/c  mice  were 
immunized using material obtained from purifications performed as described 
above.  The  first two immunizations (2  wk apart)  were  subcutaneous and  used 
HMW-BCGF in complete Freund's adjuvant. The third immunization was per- 
formed 2 wk after the second and was intravenous and intraperitoneal.  Hybrid- 
omas obtained from fusion of the spleens of these mice with NS-1  were screened 
for their ability to inhibit HMW-BCGF-induced proliferation of anti-#-activated 
B cells. Of several screened hybridomas, BCGF/1/C2 was selected because of its 17¢a0 
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FIGURE 7.  (A)  1251-HMW-BCGF was added at 50,000  cpm to tubes containing 105 unacti- 
vated B cells,  SAC-activated B cells, unactivated T  cells, or PHA-activated T  cells in RPM1 
1640.  Unlabeled HMW-BCGF was added to different tubes at different concentrations and 
each tube shaken briefly. Tubes were allowed to sit at 4°C for 8  h  after which they were 
washed three times with PBS. After washing, cell-associated radioactivity was quantitated. (0) 
Activated B cells, (A) unactivated B cells, (O) activated T  ceils,  (A) unactivated T  cells.  (B) 
Same experiment as A except only cell-associated radioactivity on activated B cells is shown. 
Inhibition of binding of zeSI-HMW-BCGF  is shown by cold HMW-BCGF (O from A) and by 
cold IL-2 (A). 
very potent inhibitory activity and was expanded in mouse ascites. The IgG from 
this  ascites  was  purified  and  assayed  for  inhibitory  activity  (Table  III).  The 
BCGF/1/C2  antibody  inhibited  the  HMW-BCGF-  but  not  the  LMW-BCGF- 
induced B cell proliferation in a dose-dependent manner, while a control mouse 
ascites  with  a  similar  concentration  of immunogtobulin  had  no  effect.  Thus, 
BCGF/1/C2 antibody was functionally specific for HMW-BCGF. Table III also 
demonstrates that the BCGF/1/C2 antibody used at a concentration  maximally 
suppressive for B cell proliferation  induced by HMW-BCGF, had no effect on 
either  PHA-stimulated T  cell proliferation or IL-2-induced proliferation  of the 
IL-2-dependent T  cell line,  HT-2. To determine actual binding of BCGF/1/C2 
antibody to HMW-BCGF, we performed Western blot analysis of HMW-BCGF, 1328  MONOCLONAL  ANTIBODY  TO  HMN-BCGF 
TABLE  II1 
Ability of lgG Antibody Produced by BCGF/1/C2 to Inhibit HMW-BCGF Activity 
[~H]Thymidine 
Cells  Factor added*  Antibody added**  incorporation 
Anti-/~-stimulated B 
ceils 
T  lymphocyte  ~ 
HT-2** 
None  --  1,905 ±  343 
HMW-BCGF  §  25%  --  32,211  ±  1,588 
12.5  --  28,185 ±  1,146 
5  --  8,324 +  1,366 
2.5  --  3,607 ±  1,350 
0.5  --  1,530 -  90 
25  BCGF/1/C2  0.15gg*  5,718±3,593 
25  0.10  9,116 +  3,872 
25  0.05  13,691  ±- 2,365 
25  0.02  16,192 ±  2,510 
25  0.01  17,500 ±  1,202 
25  0.002  18,448  +  7,895 
25  Control ascites 25% vol/vot  30,259 +  585 
LMW-BCGF'  25%  --  23,579±  1,732 
5  --  16,220 +  802 
25  BCGF/1/C2  0.10 ug  17,765+2,740 
25  0.02  18,880 ±  1,753 
--  --  1,887 +  166 
PHA (I t~g/ml)  --  35,262  +  1,303 
PHA(I ug/ml)  BCGF/1/C2  0.1  gg  31,188-  100 
--  --  1,936 ±  230 
2 U IL-2  --  29,335  ±  1,909 
2 U IL-2  BCGF/1/C2  0.1  ug  23,939 ±  2,733 
* Factor and antibody were added as indicated at time zero to human peripheral B cells stimulated 
with 15 #g/ml anti-it as described in Materials and Methods. Cells were pulsed with 1 gCi/well of 
[3Hltbymidine for the last  18 h of a 72-h culture and then harvested. 
* The antibody was at 2.5 mg/ml. 
§ Namalva was used as the source of HMW-BCGF here although similar results were obtained with 
T-ALL (F). 
The T-T hybridoma 3B3 is the source of LMW-BCGF. 
T  lymphocytes were purified from peripheral blood mononuclear cells by rosetting once with 2- 
aminoethylisothiuronium.  PHA  and/or  antibody  was  added  on  day  0  as  indicated  to  96-well 
Costar plates (100,000 cells per well) with [~H]thymidine added for the last  18 h of a 96-h culture 
period. 
** HT-2 cells were washed three times and then put in culture with IL-2 (from the MLA-144 gibbon 
line) and/or antibody, as indicated,  in  96-well Costar plates at  5,000  cells per well. Cells were 
pulsed with 1 gCi/well for the last 4 h of an 18-h culture period and then harvested for evaluation 
of [SH]thymidine incorporation. 
LMW-BCGF  (3B3),  IL-2, and  PHA,  using BCGF/1/C2  IgG.  Fig. 8  demonstrates 
that  BCGF/1/C2  IgG  bound  to the  HMW-BCGF  produced  by  Namalva  and  T- 
ALL  but  failed  to  bind  to  LMW-BCGF  produced  by  3B3  or  to  purified  IL-2 
produced  by theJurkat  line. BCGF/1/C2  showed  no binding  to PHA  by a  similar 
analysis (data not shown).  BCGF/1/C2,  therefore,  demonstrated  antigenic as well 
as  functional  specificity  for  HMW-BCGF,  and  we  concluded  that  BCGF/1/C2 
was a  monoclonal  antibody  which  blocked  the cell-binding site of HMW-BCGF. 
Having  demonstrated  specificity  of  BCGF/1/C2  for  HMW-BCGF,  we  next 
investigated  whether  BCGF/1/C2  could absorb  H MW-BCGF  from  supernatants AMBRUS  ET  AL.  1329 
FIGURE 8.  Western blotting using BCGF]I/C2 antibody. (1) LMW-BCGF (3B3), (2) HMW- 
BCGF (Namalva), (3) HMW-BCGF (T-ALL), (4) IL-2 (purified from Jurkat line). 
TABLE  IV 
Absorption of BCGF Activity  from Culture Supernatant by Sepharose- 
coupled BCGF/1/C2 Antibody 
Concen-  [3H]Thymidine 
Supernatant  tration 
(vol/vol)  incorporation 
% 
None 
T-ALL crude supernatant  25 
PBS washed BCGF/1/C2 Sepharose*  25 
Glycine washed BCGF]I/C2 Sepharose*  25 
Control Sepharose PBS wash  ~  25 
Control Sepharose glycine wash  25 
1,274 --- 214 
10,833  +  1,269 
2,496 +  54 
9,620 +  815 
8,138 --- 224 
1,530 -+ 199 
* Effluent  from  BCGF/1/C2  Sepharose  column  washed  with  PBS  and 
then concentrated to original sample volume. 
Effluent from BCGF/1/C2 Sepharose column washed with 0.2 M glycine 
(pH 3.0), dialyzed against PBS, and then concentrated to original sample 
volume. 
Control Sepharose contained rabbit antibody to media proteins; protocol 
was as for BCGF/1]C2 Sepharose column. 
containing  large  amounts  of other  proteins.  Again,  this  was  examined  both 
functionally and chemically. Table  IV  demonstrates that  a  column containing 
BCGF/1/C2  coupled to Sepharose bound the HMW-BCGF activity specifically. 
After loading a  supernatant containing HMW-BCGF  on  the column, washing 
with PBS eluted minimal if any BCGF activity. However, washing with 0.2  M 
glycine, pH 3.0, eluted most of the original BCGF activity from the supernatant. 
In contrast, a  column containing antibody directed towards media proteins of 
HB102  coupled to Sepharose did not specifically bind the HMW-BCGF in the 
supernatant.  The majority of BCGF  activity was eluted with PBS  in this case, 
rather than with glycine. To test the specificity of the absorption by BCGF/1/ 
C2  Sepharose,  we internally labeled proteins produced by T-ALL using [3H]- 
amino acids  in  amino acid-deficient media at  the  time  that  the  cell  line  was 
stimulated  to  produce  HMW-BCGF  with  PHA.  The  supernatant  was  then 
concentrated and entered onto the column containing BCGF/1/C2 IgG coupled 1330  MONOCLONAL  ANTIBODY  TO  HMN-BCGF 
to Sepharose. The material eluted by the 2 M glycine, pH 3.0 wash migrated to 
the  region  of  60,000  mol  wt  by  SDS-PAGE,  with  a  retardation  factor  (R~) 
identical to the purified HMW-BCGF (data not shown). The PBS wash from this 
column contained many other internally labeled proteins while the glycine wash 
from the column with anti-media immunoglobulin coupled to Sepharose did not 
contain this internally labeled, 60,000 mol wt protein. Thus, the 60,000 tool wt, 
internally labeled protein that eluted with glycine from the BCGF/1/C2 antibody 
column was HMW-BCGF. Furthermore,  the BCGF/1/C2 antibody did not bind 
any other internally labeled proteins produced by T-ALL. 
Discussion 
In  a  previous  study  (9),  we  demonstrated  the  production  of HMW-BCGF 
activity  by certain  human  B  and  T  cell  lines.  In  the  present  study,  we  have 
purified this active material  to biochemical homogeneity, using immunoabsorp- 
tion,  HPLC, and preparative  isoelectric focusing.  Despite the low overall yield 
of this procedure, sufficient HMW-BCGF was generated to immunize mice and 
produce  a  monoclonal  antibody.  The  iodinated  product  of the  purification 
scheme produced a single band by SDS-PAGE and demonstrated specific binding 
to activated B cells that could be inhibited by unlabeled HMW-BCGF but not by 
purified IL-2. One of the monoclonal antibodies developed by immunizing mice 
with the purified HMW-BCGF was demonstrated to inhibit the proliferation of 
activated  B  cells  stimulated  with  HMW-BCGF,  but  had  no  affect  on  PHA- 
induced proliferation of normal T  cells nor on IL-2-induced proliferation of the 
IL-2-dependent T  cell line,  HT-2. The monoclonal antibody was demonstrated 
by Western  blotting  to  bind  to  BCGF from  two  different  sources but  not  to 
LMW-BCGF, IL-2, or PHA. Finally, when coupled to Sepharose, the monoclonal 
antibody  specifically absorbed all  BCGF activity and  recognized  only a  single 
protein  in  T-ALL supernatants  that comigrated with purified  HMW-BCGF by 
SDS-PAGE. 
The purification of various lymphokines by different investigators has revealed 
that  certain  biochemical procedures were associated with poor functional  lym- 
phokine recovery. Smith et al. (13) and Yoshizaka et al. (34) noted major losses 
of functional lymphokine with isoelectric focusing in the purification of IL-2 and 
B cell differentiation  factor (BCDF), respectively.  Henderson  et al.  (35) noted 
moderate  loss of IL-2  activity in  a  one-step purification  of IL-2  using  reverse 
phase HPLC.  We found that  both isoelectric focusing and  reverse phase chro- 
matography were essential to separate HMW-BCGF from other proteins in the 
culture supernatant.  This explains why we obtained an overall functional  yield 
of only  0.3%.  Nevertheless,  we  generated  sufficient  HMW-BCGF  to  use  for 
immunizing  mice to make monoclonal antibodies and to label for investigation 
of the specific binding of HMW-BCGF to lymphocytes. This represents a consid- 
erable improvement over other isolation procedures, since previously published 
techniques  were able to obtain  only enough protein  to perform  selected func- 
tional studies with the final product (36-38). 
The  end  result  of the  purification  was a  60,000  tool wt protein  that,  when 
iodinated, produced a single band by SDS-PAGE. This protein bound specifically 
to activated but not resting B cells, suggesting that a receptor for HMW-BCGF AMBRUS ET  AL.  1331 
is present only on activated B cells. This supports the model of B cell function 
in  which resting  B  cells must be activated by antigen  or a  surface crosslinking 
signal before they can respond to BCGF (20, 32, 33). Furthermore,  the lack of 
binding  of our  labeled  HMW-BCGF  to  resting  or  activated  T  cells  parallels 
previous studies (39, 40) demonstrating  that anti-#-activated  B cells but not T 
cells absorb BCGF activity from culture supernatants.  The existence of purified 
HMW-BCGF in sufficient quantities  to perform binding studies has allowed us 
to put these previous phenomenologic observations on a quantitative, biochemi- 
cal  basis.  Further  studies  evaluating  the  nature  of the  receptor(s)  for  HMW- 
BCGF and its expression on subpopulations of B cells are currently in progress. 
The use of monoclonal antibodies to study B cell function in the past (41) has 
generally involved evaluation of surface antigens expressed by different subpop- 
ulations of B cells. Recently, Jung and Fu (42) described a  monoclonal antibody 
that blocks growth factor-dependent B cell proliferation.  This antibody may be 
directed towards a growth factor receptor, since it was produced by immunizing 
mice with pokeweek mitogen-stimulated  lymphocytes. One other antibody that 
recognizes a  BCGF has been reported (22); however, the one described here is 
the first reported monoclonal antibody to a human BCGF. Antibodies to HMW- 
BCGF can be used to help clarify the physiologic roles of HMW-BCGF as well 
as to aid in identification and quantitation  of HMW-BCGF in vivo and in vitro. 
Overall, the present studies have several important implications. They provide 
definitive evidence that HMW-BCGF is a lymphokine distinct from LMW-BCGF 
or IL-2, both antigenically and functionally. We have previously shown (9) that, 
by biochemical and functional criteria,  HMW-BCGF can be distinguished  from 
IL-1, IL-2, IFN, and  LMW-BCGF. Nevertheless, variability in the size of many 
lymphokines (43-45)  makes distinction  based on  size alone difficult, especially 
when their activities can be similar or overlapping.  Glycosylation, which affects 
Stokes radius and migration  in SDS gels, can affect the activity of a  lymphokine 
as  well.  IgE-binding  factors  that  have  identical  protein  backbones  can  have 
suppressive or enhancing activity for the production of IgE antibody depending 
upon their degree of glycosylation (46). Thus, purification of the various growth 
factors and direct comparison of their binding to cells is required for definitive 
distinction  among them.  Using purified  HMW-BCGF and  IL-2,  we have dem- 
onstrated  that  IL-2 does not inhibit the binding of HMW-BCGF to activated B 
cells. Furthermore,  BCGF/1/C2 blocks the activity of HMW-BCGF but does not 
block either  the activity of LMW-BCGF or the ability of IL-2  to enhance  the 
proliferation  of an  IL-2-dependent  T  cell  line.  Finally,  BCGF/1/C2  binds  to 
HMW-BCGF in Western blots, but fails to bind to LMW-BCGF or IL-2. Thus, 
these studies  have clearly demonstrated  that  HMW-BCGF is a  unique  growth 
factor, distinct from IL-2 and  LMW-BCGF. HMW-BCGF is in fact a significant 
product  of both  T-ALL  and  Namalva,  as  it  can  be  internally  labeled by the 
addition  of [~H]amino  acids  to  both  cell  lines  grown  in  amino  acid-deficient 
media.  Moreover,  HMW-BCGF  produced  by the  two cell  lines  is  apparently 
identical  since  the  product  of both  lines  is recognized  by a  single  monoclonal 
antibody, and the two BCGFs have identical molecular weights. The monoclonal 
antibody data suggest also that the very high molecular weight BCGF (150,000- 
200,000) found on the TSK G3000  SW column  is antigenically  related  to the 1332  MONOCLONAL ANTIBODY TO  HMN-BCGF 
HMW-BCGF that we have purified, since BCGF/1/C2 absorbs all BCGF activity 
from crude T-ALL supernatants. Since only the 60,000  mol wt species was seen 
on  SDS-PAGE  of the BCGF/1/C2-adsorbed  material  from T-ALL, it is  likely 
that  the  HMW  species  seen  on  gel  permeation  chromatography represents  a 
complex of the species that we have purified, formed either by self-aggregation 
or by binding to other proteins in the supernatant. 
Finally, purification  of HMW-BCGF  will  allow  amino  acid  sequencing  and 
subsequent cloning of the gene responsible for the production of HMW-BCGF. 
The monoclonal antibody BCGF/1/C2 will help in rapid purification of HMW- 
BCGF, rapid screening of HMW-BCGF-producing cells, and further exploration 
of the precise role of HMW-BCGF in the regulation of human B cell function. 
Summary 
High molecular weight B cell growth factor (HMW-BCGF) produced by a  T 
cell  line was purified to homogeneity and demonstrated to bind specifically to 
activated human B cells. A  monoclonal antibody to HMW-BCGF was developed 
that (a)  specifically inhibited the activity of HMW-BCGF in  enhancing  B  cell 
proliferation, (b) specifically bound to HMW-BCGF in Western blots, (c) specif- 
ically absorbed  HMW-BCGF activity from culture supernatants, and (d) specifi- 
cally absorbed  an  internally labeled  protein  from  T-ALL  supernatant  which 
comigrates with  HMW-BCGF on  sodium dodecyl sulfate-polyacrylamide gels. 
This  antibody should help  in  cloning the  gene  for  HMW-BCGF and  further 
exploring the physiologic roles of HMW-BCGF. 
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